Blood-brain barrier and feeding: Regulatory roles of saturable transport systems for ingestive peptides

Current Pharmaceutical Design

Volumn 14, Issue 16, 2008, Pages 1615-1619

  Kastin, Abba J ^a   Pan, Weihong ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Blood brain barrier; GALP; Insulin; Leptin; Mahogany peptide; Passive diffusion; Saturable transport; Urocortin

Indexed keywords

ADIPONECTIN; ADRENOMEDULLIN; AGOUTI RELATED PROTEIN; ALBUMIN; AMYLIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CYCLO(HISTIDYLPROLINE); FIBROBLAST GROWTH FACTOR 21; GALANIN LIKE PEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; INTERMEDIN; LEPTIN; MAHOGANY [1377-1428]; MELANIN CONCENTRATING HORMONE; NESFATIN 1; NEUROPEPTIDE Y; NUCLEAR FACTOR Y; OBESTATIN; OREXIN A; OREXIN B; PEPTIDE; PEPTIDE YY [3-36]; PROTEIN; SOMATOMEDIN; UROCORTIN;

BLOOD BRAIN BARRIER; FEEDING BEHAVIOR; HUMAN; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTAKE; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SATURABLE TRANSPORT; TRANSPORT KINETICS;

ALBUMINS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; FEEDING BEHAVIOR; HUMANS; PEPTIDES; PROTEIN BINDING;

EID: 48949117592     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784705423     Document Type: Review

References (83)

1. Kastin AJ, Akerstrom V, Pan W. Validity of multiple-time regression analysis in measurement of tritiated and iodinated leptin crossing the blood-brain barrier meaningful controls. Peptides 2001; 22: 2127-36.
2. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999; 289: 219-23.
3. Pan W, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: Obestatin, ghrelin, and adiponectin. Peptides 2006; 27: 911-6.
4. Pan W, Kastin AJ. In: Gozes I Ed, Neuropeptide techniques. Humana Press: Totowa, NJ, 2007; 97-113.
5. Pan W, Kastin AJ. Adipokines and the blood-brain barrier. Peptides 2007; 28: 1317-30.
6. Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, et al. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006; 55: 141-7.
7. Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997; 18: 1431-9.
8. Kastin AJ, Hahn K, Zadina JE. Regional differences in peptide degradation by rat cerebral microvessels: A novel regulatory mechanism for communication between blood and brain. Life Sci 2001; 69: 1305-12.
9. Kastin AJ, Akerstrom V, Hackler L. Agouti-related protein (83-132) aggregates and crosses the blood-brain barrier slowly. Metabolism 2000; 49: 1444-8.
10. Pan W et al. Selective tissue uptake of AgRP (82-131) and its modulation by fasting. Endocrinology 2005; 146: 5533-9.
11. Kastin AJ, Akerstrom V, Hackler L. Food deprivation decreases blood galanin-like peptide and its rapid entry into the brain. Neuroendocrinology 2001; 74: 423-32.
12. Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into the brain. Am J Physiol 1999; 270: E479-82.
13. Kastin AJ, Akerstrom V. Entry of CART into brain is rapid but not inhibited by excess CART or leptin. Am J Physiol 1999; 277: E901-4.
14. Wilson JF, Anderson S, Snook G, LLewellyn KD. Quantification of the permeability of the blood-CSP barrier to α-MSH in the rat. Peptides 1984; 5: 681-5.
15. Wilson JF. law permeability of the blood-brain barrier to nanomolar concentrations of immunoreactive alpha-melanotropin. Psychopharmacology (Berl) 1998; 96: 262-6.
16. Banks WA, Kastin AJ. Permeability of the blood-brain barrier to melanocortins. Peptides 1995; 16: 1157-61.
17. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci 1995; 57: 1993-2001.
18. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994; 135: 1753-61.
19. Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 2000; 72: 171-8.
20. Yu Y, Kastin AJ, Pan W. Reciprocal interactions of insulin and IGF-I in receptor-mediated transport across the blood-brain barrier. Endocrinology 2006; 147: 2611-5.
21. 1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 690-6.
22. Banks WA, Kastin AJ, Akerstrom V, Jaspan JB. Radioactively iodinated cyclo(His-Pro) crosses the blood-brain barrier and reverses ethanol-induced narcosis. Am J Physiol 1993; 267: E723-9.
23. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
24. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes 2003; 27: 313-8.
25. Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 2003; 306: 948-53.
26. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007; 28: 2223-8.
27. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28: 2372-81.
28. Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007; 28: 2382-6.
29. Pan W et al. Permeation of growth hormone across the blood-brain barrier. Endocrinology 2005; 146: 4898-904.
30. Pan W, Yu Y, Nyberg F, Kastin AJ. In: Nyberg F Ed, The somatotropic axis in brain function. Elsevier: San Diego, CA, 2006; 75-9.
31. Jaspan JB, Banks WA, Kastin AJ. Study of passages of peptides across the blood-brain barrier biological effects of cyclo(His-Pro) after intravenous and oral administration. Ann NY Acad Sci 1994; 739: 101-7.
32. 19-Melanin-concentrating hormone and the blood-brain barrier role of protein binding. J Neurochem 2000; 74: 385-91.
33. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmcology 1998; 37: 1553-61.
34. Kastin AJ, Akerstrom V, Hackler L, Pan W. Adrenomedullin and the blood-brain barrier. Hormones Metab Res 2001; 33: 19-25.
35. Lawrence CB, Baudoin FM, Luckman SM. Centrally administered galanin-like peptide modifies food intake in the rat: A comparison with galanin. J Neuroendocrinol 2002; 14: 853-60.
36. Hansen KR, Krasnow SM, Nolan MA, Fraley GS, Baumgartner JW, Clifton DK, et al. Activation of the sympathetic nervous system by galanin-like peptide - a possible link between leptin and metabolism. Endocrinology 2003; 144: 4709-17.
37. Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: A mechanism for regulated insulin delivery to the brain. J Clin Invest 1993; 92: 1824-30.
38. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier novel demonstration by species-specific radioimmunoassays. Peptides 1997; 18: 1257-62.
39. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier saturability at euglycemic doses of insulin. Peptides 1997; 18: 1423-9.
40. Banks WA, Kastin AJ. Regional variation in transport of pancreatic polypeptide across the blood-brain barrier. Pharmacol Biochem Behav 1995; 51: 139-47.
41. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide 1-27 and pituitary adenylate cyclase activating polypeptide 1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 690-6.
42. Kastin AJ, Akerstrom V. Differential interactions of urocortin/ corticotropin-releasing hormone peptides with the blood-brain barrier. Neuroendocrinology 2002; 75: 367-74.
43. Kastin AJ, Akerstrom V. Mahogany (1377-1428) enters brain by a saturable transport system. J Pharmacol Exp Ther 2000; 294: 633-6.
44. Banks WA, Tschop M, Robinson SM, Heiman M. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302: 822-7.
45. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-11.
46. Maresh GA, Maness LM, Zadina JE, Kastin AJ. In vitro demonstration of a saturable transport system for leptin across the blood-brain barrier. Life Sci 2001; 69: 67-73.
47. Kastin AJ, Akerstrom V. Fasting, but not adrenalectomy, reduces transport of leptin into the brain. Peptides 2000; 21: 679-82.
48. Kastin AJ, Akerstrom V. Glucose and insulin increase the transport of leptin through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice. Neuroendocrinology 2001; 73: 237-42.
49. Pan W, Kastin AJ. Diurnal variation of leptin entry from blood to brain involving partial saturation of the transport system. Life Sci 2001; 68: 2705-14.
50. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999; 20: 1341-5.
51. Banks WA, Clever CM, Farrell CL. Partial saturation and regional variation in the transport of leptin across the blood-brain barrier in normal weight mice. Am J Physiol 2000; 278: E1158-65.
52. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004; 53: 1253-60.
53. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006; 312: 927-30.
54. Uotani S, Bjorbaek C, Tornoe J, Flier JS. Functional properties of leptin receptor isoforms: Internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999; 48: 279-86.
55. Hileman SM, Pierroz DD, Masuzaki H, Diorbaek C, El-Haschimi K, Banks WA, et al. Characterization of short isoforms of the leptin receptor in mt cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002; 143: 775-83.
56. Maness LM, Banks WA, Kastin AJ. Persistence of blood-to-brain transport of leptin in obese leptin-deficient and leptin receptor-deficient mice. Brain Res 2000; 873: 165-7.
57. Tu H, Pan W, Feucht L, Kastin AJ. Convergent trafficking pattern of leptin after endocytosis mediated by ObRa - ObRd. J Cell Physiol 2007; 212: 215-22.
58. Tu H, Kastin AJ, Hsuchou H, Pan W. Soluble receptor inhibits leptin transport. J Cell Physiol 2008; 214: 301-5.
59. Smith JT, Mark PJ, Waddell BJ. Developmental increases in plasma leptin binding activity and tissue Ob-Re mRNA expression in the rat. J Endocrinol 2005; 184: 535-41.
60. Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem 2001; 276: 6343-9.
61. Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P. Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 1999; 20: 1449-53.
62. Levin BE, Dunn-Meynell AA, Banks WA. Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol 2004; 286: R143-50.
63. Kastin AJ, Akerstrom V, Maness LM. Chronic loss of ovarian function decreases transport of leptin into mouse brain. Neurosci Lett 2001; 310: 69-71.
64. Pan W, Kastin AJ. Interactions of cytokines with the blood-brain barrier Implications for feeding. Curr Pharm Des 2003; 9: 827-31.
65. Pan W, Kastin AJ. In: Sharma HS, Westman J Eds, Blood-spinal cord and brain barriers in health and disease. Elsevier San Diego, CA, 2004; 395-407.
66. Pan W, Kastin AJ. Polypeptide delivery across the blood-brain barrier. Curr Drug Targets CNS Neurol Disord 2004; 3: 131-6.
67. Pan W, Xiang S, Tu H, Kastin AJ. In: Dermietzel R, Spray DC, Nedergaard M Eds, Blood-brain barrier interfaces: From ontogeny to artificial barriers. Wiley-VCH: Weinheim, Germany 2006; 247-64.
68. Pan W, Kastin AJ, Daniel J, Yu C, Baryshnikova LM, von Bartheld CS, et al. TNF alpha trafficking in cerebral vascular endothelial cells. J Neuroimmunol 2007; 185: 47-56.
69. Yu C, Kastin AJ, Tu H, Pan W. Opposing effects of proteasomes and lysosomes on LIFR: Modulation by TNF. J Mol Neurosci 2007; 32: 80-9.
70. Yu C, Kastin AJ, Pan W. TNF reduces LIF endocytosis despite increasing NFkappaB-mediated gp130 expression. J Cell Physiol 2007; 213: 161-6.
71. Pan W, Tu H, Hsuchou H, Yang Y, Kastin AJ. Differential role of TNF receptors in cellular trafficking of intact TNF. Cell Physiol Biochem 2007; 20: 559-68.
72. Kastin AJ, PaB W. Editorial: Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology 2006; 147: 2086-7.
73. Rodriguez EM, Blázquez JL, Pastor FE, Peláez B, Peña P, Peruzzo B, et al. Hypothalamic tanycytes: A key component of brain-endocrine interaction. Int Rev Cytol 2005; 247: 89-164.
74. Pan W, Kastin AJ. Urocortin and the brain. Prog Neurobiol 2008; 84: 148-56.
75. Kastin AJ, Akerstrom V, Pan W. Activation of urocortin transport into brain by leptin. Peptides 2000; 21: 1811-8.
76. Pan W, Akerstrom V, Zhang J, Pejovic V, Kastin AJ. Modulation of feeding-related peptide/protein signals by the blood-brain barrier. J Neurochem 2004; 90: 455-61.
77. Kastin AJ, Akerstrom V. Pretreatment with glucose increases entry of urocortin into mouse brain. Peptides 2001; 22: 829-34.
78. Tu H, Kastin AJ, Bjorbaek C, Pan W. Urocortin trafficking in cerebral microvessel endothelial cells. J Mol Neurosci 2007; 31: 171-82.
79. Tu H, Kastin AJ, Pan W. CRH-R1 and CRH-R2 are both trafficking and signaling receptors for urocortin. Mol Endocrinol 2007; 21: 700-11.
80. Banks WA, Nichoff ML, Martin D, Farrell CL. Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res 2002; 950: 130-6.
81. Iannucci CV, Capoccia D, Calabria M, Leonetti F. Metabolic syndrome and adipose tissue: New clinical aspects and therapeutic targets. Curr Pharm Des 2007; 13(21): 2148-68.
82. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G. Visceral and subculaneous adiposity: Are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007; 13(21): 2169-75.
83. Sharma HS, Sjoquist PO, Ali SF. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: Neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 2007; 13(18): 1903-23.